Scott Hofsess

Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase

Nigel J. Liverton, John W. Butcher, Christopher F. Claiborne et al. · Journal of Medicinal Chemistry · 1999 · 196 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

Aditya Bardia, Hope S. Rugo, Sara M. Tolaney et al. · Journal of Clinical Oncology · 2024 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Anna Kopp, Scott Hofsess, Thomas M. Cardillo et al. · Molecular Cancer Therapeutics · 2022 · 91 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors

Scott D. Edmondson, Anthony Mastracchio, Jiafang He et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

SA Hurvitz, Amit Bardia, Kevin Punie et al. · Annals of Oncology · 2022 · 24 citations · Full text

Medicine, Oncology, Pharmacology +16